{"id":11378,"date":"2021-10-27T16:43:47","date_gmt":"2021-10-27T14:43:47","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=11378"},"modified":"2022-03-31T17:28:08","modified_gmt":"2022-03-31T15:28:08","slug":"germany-ema-and-eu-commission-offer-flexibility-instead-of-intervention","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/jp\/publications\/germany-ema-and-eu-commission-offer-flexibility-instead-of-intervention\/","title":{"rendered":"Alignment of Pharmaceutical Strategy for Europe with the Action Plan on IP, 2021"},"content":{"rendered":"\n<p>by Dr <a href=\"https:\/\/www.maiwald.eu\/en\/team\/gisela-grabow\/\">Gisela <\/a><a href=\"https:\/\/www.maiwald.eu\/jp\/team\/gisela-grabow\/\">Grabow<\/a><\/p>\n\n\n\n<p>in Managing Intellectual Property<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11378","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":6,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11378\/revisions"}],"predecessor-version":[{"id":16972,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11378\/revisions\/16972"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=11378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}